We are live on ! Find out more
AKTS

Aktis Oncology
AKTS

69 hedge funds and large institutions have $630M invested in Aktis Oncology in 2026 Q1 according to their latest regulatory filings, with 69 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

75.42% more ownership

Funds ownership: 0% → 75.42% (+75%)

Holders
69
Holders Change
+69
Holders Change %
–
% of All Funds
0.85%
Holding in Top 10
4
Holding in Top 10 Change
+4
Holding in Top 10 Change %
% of All Funds
0.05%
New
69
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
MB
MPM BioImpact
Massachusetts
+$93.9M
2
EC
EcoR1 Capital
California
+$93.7M
3
BOCH
Blue Owl Capital Holdings
New York
+$61.4M
4
Wellington Management Group
Wellington Management Group
Massachusetts
+$45M
5
T. Rowe Price Investment Management
T. Rowe Price Investment Management
Maryland
+$41.2M

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
Northern Trust
26
Northern Trust
Illinois
$2.67M +$2.9M +149,476 New
VFT
27
Vanguard Fiduciary Trust
Pennsylvania
$2.28M +$2.47M +127,395 New
VPM
28
Vanguard Portfolio Management
Pennsylvania
$2.15M +$2.34M +120,322 New
Ameriprise
29
Ameriprise
Minnesota
$1.84M +$2M +102,925 New
TD Asset Management
30
TD Asset Management
Ontario, Canada
$1.81M +$1.96M +100,962 New
LCM
31
Laurion Capital Management
New York
$1.79M +$1.94M +100,000 New
SFM
32
Soros Fund Management
New York
$1.79M +$1.94M +100,000 New
WP
33
Woodline Partners
California
$1.79M +$1.94M +100,000 New
Citadel Advisors
34
Citadel Advisors
Florida
$1.34M +$1.46M +75,000 New
Bank of America
35
Bank of America
North Carolina
$1.25M +$1.36M +69,926 New
Manulife (Manufacturers Life Insurance)
36
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$841K +$912K +46,993 New
Bank of New York Mellon
37
Bank of New York Mellon
New York
$767K +$833K +42,901 New
Morgan Stanley
38
Morgan Stanley
New York
$550K +$597K +30,723 New
Goldman Sachs
39
Goldman Sachs
New York
$540K +$586K +30,163 New
RAM
40
Readystate Asset Management
Illinois
$537K +$582K +30,000 New
GCM
41
Ghisallo Capital Management
Massachusetts
$447K +$485K +25,000 New
SGM
42
Seven Grand Managers
New York
$447K +$485K +25,000 New
N
43
Nuveen
North Carolina
$438K +$475K +24,468 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$376K +$408K +21,033 New
D.E. Shaw & Co
45
D.E. Shaw & Co
New York
$305K +$331K +17,062 New
ZP
46
Zimmer Partners
New York
$268K +$291K +15,000 New
Universal-Beteiligungs- und Servicegesellschaft
47
Universal-Beteiligungs- und Servicegesellschaft
Germany
$254K +$275K +14,185 New
Deutsche Bank
48
Deutsche Bank
Germany
$252K +$273K +14,080 New
XT
49
XTX Topco
Cayman Islands
$250K +$272K +13,990 New
Invesco
50
Invesco
Georgia
$217K +$235K +12,113 New
1
2
3

AKTS Hedge Fund Activity: Q1 2026 in Review

69 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in Aktis Oncology (AKTS) for Q1 2026, worth a combined $630M.

Buyers outnumbered sellers: 69 funds opened new AKTS positions and 0 closed out — a net gain of 69 holders — while 0 added to existing stakes and 0 trimmed.

The largest buyer was MPM BioImpact, opening a new position worth an estimated $93.9M.

  • 69 institutional investors held Aktis Oncology (AKTS) as of Q1 2026, up from 0 in Q4 2025.
  • Funds reported $630M of Aktis Oncology stock for Q1 2026.
  • 69 funds opened new Aktis Oncology positions in Q1 2026 and 0 closed out, a net change of +69 holders.
  • The largest Aktis Oncology buyer in Q1 2026 was MPM BioImpact, an estimated $93.9M added.

Based on aggregated 13F filings for Q1 2026.